All In Biotech

NDA 205352 · Bayer Hlthcare

Aleve Pm

Diphenhydramine Hydrochloride, Naproxen Sodium · Oral

Last checked: Nov 19, 2026Latest source record: Feb 8, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Jan 17, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,141

246 Phase 3, 67 recruiting

FAERS reports

2,033

189 serious, 9 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 4, 2025.

Uses for relief of occasional sleeplessness when associated with minor aches and pains helps you fall asleep and stay asleep

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ALEVE PM · DIPHENHYDRAMINE HYDROCHLORIDE 25MG; NAPROXEN SODIUM 220MG · TABLET, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Diphenhydramine" as an intervention, any sponsor and status, largest first.

All 1,141 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product use issue466
  • drug ineffective461
  • insomnia185
  • medication error133
  • product use in unapproved indication113
  • somnolence113
  • therapeutic response unexpected103
  • incorrect drug administration duration101
  • incorrect dose administered73
  • expired product administered61
  • drug ineffective for unapproved indication60
  • feeling abnormal59

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20102
2014184
2015521
2016358
2017225
2018236
2019246
202087
202154
202240
202321
202430
202515
202614

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 557 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.